Angiogenesis pp 449-457 | Cite as

“CM101 — An Anti-Pathoangiogenic Agent: Pre-Clinical and Clinical Experiences”

  • Carl G. Hellerqvist
Part of the NATO ASI Series book series (NSSA, volume 298)


The pathophysiology of Group B Streptococcal (GBS) disease depends on the age of the neonate infected. Neonates infected at birth by GBS colonizing the birth canal may be diagnosed with early-onset disease. The symptoms are respiratory distress and cardiovascular shock (Baker and Edwards, 1995) and the gravity may vary from asymptomatic to lethal. In infants older than 1 week, late-onset disease is often associated with meningitis. GBS rarely affects normal adults, but may present in old adults with impaired peripheral circulation (diabetics) or with a compromised immune system due to cancer or other debilitating disease (Farley, Harvey, Stull, Smith, Schuchat, Wenger, and Stephens, 1993).


Complement Receptor Type Tumor Neovasculature Young Lamb Minute Time Point Cardiovascular Shock 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baker, C.J. and Edwards M.S., 1995, Group B streptococcal infections, in: Infectious Diseases of the Fetus and Newborn Infant, 4th Edition (Remington, J.S. and Klein, J.O., eds.), pp. 980–1054, W.B. Saunders Co., Philadelphia, PA.Google Scholar
  2. DeVore, R., Johnson, D.R., Hellerqvist, C., Wakefield, G., Browning, P., Page, D., Sundeil, H., and Johnson, D.H., 1996, A phase I study of the anti-neovascularization drug CM101, Proceedings of ASCO Meeting, 15:1558.Google Scholar
  3. DeVore, R.F., Hellerqvist, C.G., Wakefield, G.B., Wamil, B.D., Thurman, G.B., Minton, P.A., Sundell, H.W., Yan, H.-P., Carter, C.E., Wang, Y.-F., York, G.E., Zhang, M.-H., and Johnson, D.H., 1997, A phase I study of the antineovascularization drug CM101, J. Clin. Can. Res. 3:365–372.Google Scholar
  4. Engelhardt, B., Sandberg, K., Bratton, D., Van den Abbeele, A., Grogaard, J., Hellerqvist, C., and Sundell, C., 1987, The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs, Pediatr. Res. 21:159.PubMedCrossRefGoogle Scholar
  5. Farley, M.M., Harvey, R.C., Stull, T., Smith, J.D., Schuchat, A., Wenger, J.D., Stephens, D.S., 1993, A population-bases assessment of invasive disease due to group B streptococcus in nonpregnant adults, N. Engl. J. Med. 328:1807–11.PubMedCrossRefGoogle Scholar
  6. Hellerqvist, C.G., Rojas, J., Green, R.S., Sell, S., Sundell, H., and Stahlman, M.T., 1981, Studies on group B β -hemolytic streptococcus. I. Isolation and partial characterization of an extracellular toxin, Pediatr. Res. 15:892–898.PubMedCrossRefGoogle Scholar
  7. Hellerqvist, C.G., Sundell, H., and Gettins, P., 1987, Molecular basis for group B β-hemolytic streptococcal disease, Proc. Natl. Acad. Sci., U.S.A. 84:51.PubMedCrossRefGoogle Scholar
  8. Hellerqvist, C.G., 1991, Therapeutic agent and method of inhibiting vascularization of tumors, U.S. Patent 5,010,062.Google Scholar
  9. Hellerqvist, C.G., Thurman, G.B., Page, D.L., Wang, Y.-F., Russell, B.A., Montgomery, C.A., and Sundell, H.W., 1993, Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B β -hemolytic streptococcus, J. Can. Res. Clin. Oncol. 120:63–70.CrossRefGoogle Scholar
  10. Hellerqvist, C.G., Wang, E., Wamil, B.D., Price, J.O., Yan, H.-P., Carter, C.E., Wang, Y-F., DeVore, R.F., Johnson, D.H., and Lloyd, 1997, Evidence of induced apoptosis in cancer patients treated with CM101, Proceedings of ASCO Annual Meeting.Google Scholar
  11. Quinn, T.E., Thurman, G.B., Sundell, A.K., Zhang, M., and Hellerqvist, C.G., 1995, CM101, a polysaccharide anti-tumor agent, does not inhibit wound healing in murine models, J. Can. Res. Clin. Oncol. 121:253–256.CrossRefGoogle Scholar
  12. Rojas, J., Green, R.S., Hellerqvist, C.G., Olegard, R., Brigham, K.L., and Stahlman M.T., 1981, Studies on group B β-hemolytic streptococcus. H. Effects on pulmonary hemodynamics and vascular permeability in unanesthetized sheep, Pediatr. Res. 15:899–904.PubMedCrossRefGoogle Scholar
  13. Rojas, J., Larsson, L.E., Ogletree, M.L., Brigham, K.L., and Stahlman, M.T., 1983, Effects of cyclooxygenase inhibition on the response to group B streptococcal toxin in sheep, Pediatr. Res. 17:107–110.PubMedCrossRefGoogle Scholar
  14. Rojas, J., Larrson, L.E., Hellerqvist, C.G., Brigham, K.L., Gray, M.E., and Stahlman, M.T., 1983, Pulmonary hemodynamic and ultrastructural changes associated with group B β-hemolytic streptococcal toxemia in adult sheep and newborn lambs, Pediatr. Res. 17:1002–1008.PubMedCrossRefGoogle Scholar
  15. Sandberg, K., Engelhardt, B., Hellerqvist, C.G., and Sundeil H., 1987, Pulmonary response to group B streptococcal toxin in young lambs, J. Appl. Physiol 63:2024–2030.PubMedGoogle Scholar
  16. Sandberg, K., Edberg, K.E., Fish, W., Parker, R.A, Hellerqvist, C.G., and Sundell, H.W., 1992, Thromboxane receptor blockage (SQ 29548) in group B streptococcal (GBS) toxin challenge in young lambs, Pediatr. Res. 35:571–579.CrossRefGoogle Scholar
  17. Sundell, H.W., Yan, H.-P., Wu, K., Wamil, B.D., Gaddipati, R., Carter, C.E., Stahlman, MT., and Hellerqvist, C.G., 1996, Isolation and identification of group B β-hemolytic streptococcal (GBS) toxin from septic newborn infants, Pediatr. Res. 39:302A.CrossRefGoogle Scholar
  18. Thurman, G.B., Russell, B.A., York, G.E., Wang, Y.-F., Page, D.L., Sundell, H.W., and Hellerqvist, C.G., 1994, Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors, J. Can. Res. Clin. Oncol. 120:479–484.CrossRefGoogle Scholar
  19. Thurman, G.B., Page, D.L., Wamil, B.D., Wilkinson, L.E., Kasami, M., and Hellerqvist, C.G., 1996, Acute inflammatory changes in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS toxin), J. Can. Res. Clin. Oncol. 122:549–553.CrossRefGoogle Scholar
  20. Vetvicka, V., Thornton, B.P., and Ross, G.D., 1996, Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, J. Clin. Invest. 98(1):50–61.PubMedCrossRefGoogle Scholar
  21. Wamil, B.D., Abramovitch, R., Wang, E., Neeman, M., Hellerqvist, C.G., 1997, CMI01 Inhibits VEGF Induced Tumor Neovascularization as Determined by MRI and RT-PCR, Proceedings of the 88th Annual American Association for Cancer Research Meeting.Google Scholar
  22. Wamil, B.D., Thurman, G.B., DeVore, R.F., Wakefield, G, Johnson, D.H., and Hellerqvist, C.G., 1997, Soluble E-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial. J. Can. Res. Clin. Oncol. 123(3):173–179.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Carl G. Hellerqvist
    • 1
  1. 1.Department of BiochemistryVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations